5-Amino-1MQ vs Tesamorelin
Both 5-Amino-1MQ and Tesamorelin are used for fat-loss. Here's how their evidence, dosing, and regulatory status actually compare.
5-Amino-1MQ
Evidence C+5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
View full 5-Amino-1MQ profile →Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →Side-by-Side
| Attribute | 5-Amino-1MQ | Tesamorelin |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — small-molecule research compound (NNMT inhibitor) | FDA-approved for HIV-associated lipodystrophy |
| Typical Dose | 50–150 mg orally daily (research-only) | 2 mg daily (subcutaneous) |
| Clinics Indexed | 31 | 178 |
| Categories | fat-loss, longevity | growth-hormone, fat-loss |
Key reported benefits — 5-Amino-1MQ
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.